Trametinib Dimethyl Sulfoxide
Trametinib dimethyl sulfoxide is the dimethyl sulfoxide solvate form of trametinib, an allosteric MEK1/MEK2 inhibitor used in combination with BRAF inhibitors for BRAF-mutated cancers. See trametinib for complete pharmacological details. This solvate form is the pharmaceutical formulation used in approved oral tablets.
Moleküler Ağırlık
693,5000 g/mol
TPSA
138,00 Ų
Terapötik Alanlar
Etki Mekanizması
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1.C[S+](C)[O-]
InChI
InChI=1S/C26H23FIN5O4.C2H6OS/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34;1-4(2)3/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34);1-2H3
Molecular Formula
C28H29FIN5O5S
HBD / HBA
2 / 8
Döndürülebilir Bağlar
5
Ağır Atomlar
41
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Trametinib dimethyl sulfoxide is the dimethyl sulfoxide solvate form of trametinib, an allosteric MEK1/MEK2 inhibitor used in combination with BRAF inhibitors for BRAF-mutated cancers. See trametinib for complete pharmacological details. This solvate form is the pharmaceutical formulation used in approved oral tablets.
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.
Yes, Trametinib Dimethyl Sulfoxide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2105741. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 50992434. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trametinib-dimethyl-sulfoxide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trametinib-dimethyl-sulfoxide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trametinib-dimethyl-sulfoxide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trametinib-dimethyl-sulfoxide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trametinib-dimethyl-sulfoxide"></drugfyi-drug>